

Francesco Giorgino

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1135594/publications.pdf>

Version: 2024-02-01

245
papers

11,996
citations

28274

55
h-index

34986

98
g-index

256
all docs

256
docs citations

256
times ranked

16036
citing authors

#	ARTICLE	IF	CITATIONS
1	Oxidative stress and reactive oxygen species in endothelial dysfunction associated with cardiovascular and metabolic diseases. <i>Vascular Pharmacology</i> , 2018, 100, 1-19.	2.1	805
2	Insulin receptor phosphorylation, insulin receptor substrate-1 phosphorylation, and phosphatidylinositol 3-kinase activity are decreased in intact skeletal muscle strips from obese subjects.. <i>Journal of Clinical Investigation</i> , 1995, 95, 2195-2204.	8.2	457
3	Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. <i>Lancet</i> , The, 2021, 398, 583-598.	13.7	274
4	The GH/IGF1 axis and signaling pathways in the muscle and bone: mechanisms underlying age-related skeletal muscle wasting and osteoporosis. <i>Journal of Endocrinology</i> , 2010, 205, 201-210.	2.6	267
5	The IGF-I Signaling Pathway. <i>Current Pharmaceutical Design</i> , 2007, 13, 663-669.	1.9	263
6	Feasibility and effectiveness of a disease and care management model in the primary health care system for patients with heart failure and diabetes (Project Leonardo). <i>Vascular Health and Risk Management</i> , 2010, 6, 297.	2.3	235
7	Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. <i>Lancet Diabetes and Endocrinology</i> , the, 2017, 5, 887-897.	11.4	231
8	Vascular Risk Factors and Markers of Endothelial Function as Determinants of Inflammatory Markers in Type 1 Diabetes: The EURODIAB Prospective Complications Study. <i>Diabetes Care</i> , 2003, 26, 2165-2173.	8.6	199
9	Continuous Subcutaneous Glucose Monitoring in Diabetic Patients. <i>Diabetes Care</i> , 2002, 25, 347-352.	8.6	192
10	Regional differences of insulin action in adipose tissue: insights from <i>in vivo</i> and <i>in vitro</i> studies. <i>Acta Physiologica Scandinavica</i> , 2005, 183, 13-30.	2.2	192
11	Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2). <i>Diabetes Care</i> , 2015, 38, 2241-2249.	8.6	184
12	Very-low-calorie ketogenic diet (VLCKD) in the management of metabolic diseases: systematic review and consensus statement from the Italian Society of Endocrinology (SIE). <i>Journal of Endocrinological Investigation</i> , 2019, 42, 1365-1386.	3.3	167
13	Cross-Talk between PPAR and Insulin Signaling and Modulation of Insulin Sensitivity. <i>PPAR Research</i> , 2009, 2009, 1-12.	2.4	162
14	Glucocorticoid regulation of insulin receptor and substrate IRS-1 tyrosine phosphorylation in rat skeletal muscle <i>in vivo</i> .. <i>Journal of Clinical Investigation</i> , 1993, 91, 2020-2030.	8.2	160
15	Insulin receptor expression and function in human breast cancer cell lines. <i>Cancer Research</i> , 1992, 52, 3924-30.	0.9	157
16	The sentrin-conjugating enzyme mUbc9 interacts with GLUT4 and GLUT1 glucose transporters and regulates transporter levels in skeletal muscle cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 1125-1130.	7.1	156
17	The Role of Oxidative Stress in Cardiac Disease: From Physiological Response to Injury Factor. <i>Oxidative Medicine and Cellular Longevity</i> , 2020, 2020, 1-29.	4.0	149
18	Intrauterine Growth Restriction in Humans Is Associated with Abnormalities in Placental Insulin-Like Growth Factor Signaling. <i>Endocrinology</i> , 2005, 146, 1498-1505.	2.8	138

#	ARTICLE	IF	CITATIONS
19	Zinc Transporter 8 Antibodies Complement GAD and IA-2 Antibodies in the Identification and Characterization of Adult-Onset Autoimmune Diabetes. <i>Diabetes Care</i> , 2010, 33, 104-108.	8.6	136
20	Efficacy and safety of very low calorie ketogenic diet (VLCKD) in patients with overweight and obesity: A systematic review and meta-analysis. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2020, 21, 5-16.	5.7	136
21	Diagnostic Utility of Thyroglobulin Detection in Fine-Needle Aspiration of Cervical Cystic Metastatic Lymph Nodes from Papillary Thyroid Cancer with Negative Cytology. <i>Thyroid</i> , 2003, 13, 1163-1167.	4.5	135
22	Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2532-2540.	4.4	133
23	Insulin and Insulin Receptors in Adipose Tissue Development. <i>International Journal of Molecular Sciences</i> , 2019, 20, 759.	4.1	129
24	Fat depot-related differences in gene expression, adiponectin secretion, and insulin action and signalling in human adipocytes differentiated in vitro from precursor stromal cells. <i>Diabetologia</i> , 2008, 51, 155-164.	6.3	125
25	Factors associated with progression to macroalbuminuria in microalbuminuric Type 1 diabetic patients: the EURODIAB Prospective Complications Study. <i>Diabetologia</i> , 2004, 47, 1020-8.	6.3	123
26	Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. <i>European Journal of Endocrinology</i> , 2010, 163, 301-308.	3.7	111
27	Efficacy of thermal ablation in benign non-functioning solid thyroid nodule: A systematic review and meta-analysis. <i>Endocrine</i> , 2020, 67, 35-43.	2.3	108
28	Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program. <i>Diabetes/Metabolism Research and Reviews</i> , 2016, 32, 776-790.	4.0	105
29	Performance of Five Ultrasound Risk Stratification Systems in Selecting Thyroid Nodules for FNA. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 1659-1669.	3.6	105
30	Effects of contractile activity on tyrosine phosphoproteins and PI 3-kinase activity in rat skeletal muscle. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1995, 268, E987-E995.	3.5	103
31	Gender differences in serum leptin in obese people: relationships with testosterone, body fat distribution and insulin sensitivity. <i>European Journal of Clinical Investigation</i> , 1997, 27, 1016-1024.	3.4	103
32	Dehydroepiandrosterone Stimulates Glucose Uptake in Human and Murine Adipocytes by Inducing GLUT1 and GLUT4 Translocation to the Plasma Membrane. <i>Diabetes</i> , 2004, 53, 41-52.	0.6	102
33	Interaction between the Grb10 SH2 Domain and the Insulin Receptor Carboxyl Terminus. <i>Journal of Biological Chemistry</i> , 1996, 271, 8882-8886.	3.4	99
34	Intensive Structured Self-Monitoring of Blood Glucose and Glycemic Control in Noninsulin-Treated Type 2 Diabetes. <i>Diabetes Care</i> , 2013, 36, 2887-2894.	8.6	98
35	Two Novel Proteins That Are Linked to Insulin-like Growth Factor (IGF-I) Receptors by the Grb10 Adapter and Modulate IGF-I Signaling. <i>Journal of Biological Chemistry</i> , 2003, 278, 31564-31573.	3.4	97
36	The Myokine Irisin Is Released in Response to Saturated Fatty Acids and Promotes Pancreatic β -Cell Survival and Insulin Secretion. <i>Diabetes</i> , 2017, 66, 2849-2856.	0.6	96

#	ARTICLE	IF	CITATIONS
37	Effect of Family History of Type 2 Diabetes on the Intima-Media Thickness of the Common Carotid Artery in Normal-Weight, Overweight, and Obese Glucose-Tolerant Young Adults. <i>Diabetes Care</i> , 2003, 26, 1230-1234.	8.6	95
38	The adapter protein Grb10 associates preferentially with the insulin receptor as compared with the IGF-I receptor in mouse fibroblasts. <i>Journal of Clinical Investigation</i> , 1997, 99, 830-837.	8.2	93
39	Elevated 1-Hour Postload Plasma Glucose Levels Identify Subjects With Normal Glucose Tolerance but Impaired β -Cell Function, Insulin Resistance, and Worse Cardiovascular Risk Profile: The GENFIEV Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 2100-2105.	3.6	92
40	Overexpression of Insulin Receptors in Fibroblast and Ovary Cells Induces a Ligand-Mediated Transformed Phenotype. <i>Molecular Endocrinology</i> , 1991, 5, 452-459.	3.7	91
41	GnRH agonist versus GnRH antagonist in in vitro fertilization and embryo transfer (IVF/ET). <i>Reproductive Biology and Endocrinology</i> , 2012, 10, 26.	3.3	90
42	Cardiovascular disease and glycemic control in type 2 diabetes: now that the dust is settling from large clinical trials. <i>Annals of the New York Academy of Sciences</i> , 2013, 1281, 36-50.	3.8	85
43	Increase in both pro-thrombotic and anti-thrombotic factors in obese premenopausal women: relationship with body fat distribution. <i>International Journal of Obesity</i> , 1997, 21, 527-535.	3.4	84
44	Insulin Signaling in Human Visceral and Subcutaneous Adipose Tissue In Vivo. <i>Diabetes</i> , 2006, 55, 952-961.	0.6	83
45	Reverse Transcriptase Inhibitors Down-Regulate Cell Proliferation <i>in Vitro</i> and <i>in Vivo</i> and Restore Thyrotropin Signaling and Iodine Uptake in Human Thyroid Anaplastic Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 5663-5671.	3.6	77
46	Urinary miRNA-27b-3p and miRNA-1228-3p correlate with the progression of Kidney Fibrosis in Diabetic Nephropathy. <i>Scientific Reports</i> , 2019, 9, 11357.	3.3	75
47	INTERFERENCE OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS ON ERYTHROPOIESIS IN KIDNEY TRANSPLANT RECIPIENTS. <i>Transplantation</i> , 1997, 64, 913-918.	1.0	73
48	Specific Increase in p85 α Expression in Response to Dexamethasone Is Associated with Inhibition of Insulin-like Growth Factor-I Stimulated Phosphatidylinositol 3-Kinase Activity in Cultured Muscle Cells. <i>Journal of Biological Chemistry</i> , 1997, 272, 7455-7463.	3.4	72
49	Lower androgenicity is associated with higher plasma levels of prothrombotic factors irrespective of age, obesity, body fat distribution, and related metabolic parameters in men. <i>Metabolism: Clinical and Experimental</i> , 1997, 46, 1287-1293.	3.4	71
50	Effects of Structured Versus Unstructured Self-Monitoring of Blood Glucose on Glucose Control in Patients With Non-insulin-treated Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials. <i>Journal of Diabetes Science and Technology</i> , 2018, 12, 183-189.	2.2	68
51	Adipose tissue, metabolic syndrome and polycystic ovary syndrome: from pathophysiology to treatment. <i>Reproductive BioMedicine Online</i> , 2009, 19, 552-563.	2.4	67
52	Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study. <i>Atherosclerosis Supplements</i> , 2017, 29, 17-24.	1.2	65
53	Low dehydroepiandrosterone circulating levels in premenopausal obese women with very high body mass index. <i>Metabolism: Clinical and Experimental</i> , 1991, 40, 187-190.	3.4	64
54	High GADA titer increases the risk of insulin requirement in LADA patients: a 7-year follow-up (NIRAD) Tj ETQq0 0 0 ggBT /Overlock 10 Tf	3.7	63

#	ARTICLE	IF	CITATIONS
55	Influence of CAG Repeat Polymorphism on the Targets of Testosterone Action. <i>International Journal of Endocrinology</i> , 2015, 2015, 1-12.	1.5	62
56	Exendin-4 protects pancreatic beta cells from palmitate-induced apoptosis by interfering with GPR40 and the MKK4/7 stress kinase signalling pathway. <i>Diabetologia</i> , 2013, 56, 2456-2466.	6.3	59
57	Diabetes and cancer: Pathophysiological fundamentals of a "dangerous affair". <i>Diabetes Research and Clinical Practice</i> , 2018, 143, 378-388.	2.8	58
58	Correction of intermittent hypoxia reduces inflammation in obese subjects with obstructive sleep apnea. <i>JCI Insight</i> , 2017, 2, .	5.0	58
59	GLP-1 receptor agonist added to insulin versus basal-plus or basal-bolus insulin therapy in type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes/Metabolism Research and Reviews</i> , 2019, 35, e3082.	4.0	57
60	Exendin-4 Prevents c-Jun N-Terminal Protein Kinase Activation by Tumor Necrosis Factor- α and Inhibits TNF- α -Induced Apoptosis in Insulin-Secreting Cells. <i>Endocrinology</i> , 2010, 151, 2019-2029.	2.8	56
61	Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 409-418.	4.4	56
62	Increased carotid IMT in overweight and obese women affected by Hashimoto's thyroiditis: an adiposity and autoimmune linkage?. <i>BMC Cardiovascular Disorders</i> , 2010, 10, 22.	1.7	55
63	The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation provides a better definition of cardiovascular burden associated with CKD than the Modification of Diet in Renal Disease (MDRD) Study formula in subjects with type 2 diabetes. <i>Atherosclerosis</i> , 2011, 218, 194-199.	0.8	55
64	Changes in tyrosine phosphorylation of insulin receptors and a 170,000 molecular weight nonreceptor protein in vivo in skeletal muscle of streptozotocin-induced diabetic rats: effects of insulin and glucose. <i>Endocrinology</i> , 1992, 130, 1433-1444.	2.8	54
65	Relationship Between Plasma Sialic Acid Concentration and Microvascular and Macrovascular Complications in Type 1 Diabetes: The EURODIAB Complications Study. <i>Diabetes Care</i> , 2001, 24, 316-322.	8.6	54
66	Effects of Streptozocin Diabetes and Diabetes Treatment by Islet Transplantation on In Vivo Insulin Signaling in Rat Heart. <i>Diabetes</i> , 2001, 50, 2709-2720.	0.6	54
67	Pegvisomant in acromegaly: an update. <i>Journal of Endocrinological Investigation</i> , 2017, 40, 577-589.	3.3	53
68	Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN). <i>Atherosclerosis Supplements</i> , 2017, 29, 11-16.	1.2	53
69	Treatment of Recent-Onset Type 1 Diabetic Patients With DiaPep277: Results of a Double-Blind, Placebo-Controlled, Randomized Phase 3 Trial. <i>Diabetes Care</i> , 2014, 37, 1392-1400.	8.6	52
70	Adherence to antihyperglycemic medications and glucagon-like peptide 1-receptor agonists in type 2 diabetes: clinical consequences and strategies for improvement. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 707-719.	1.8	52
71	Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk. <i>Cardiovascular Diabetology</i> , 2020, 19, 196.	6.8	52
72	Oocyte morphological abnormalities in overweight women undergoing <i>in vitro</i> fertilization cycles. <i>Gynecological Endocrinology</i> , 2011, 27, 880-884.	1.7	51

#	ARTICLE	IF	CITATIONS
73	Differences in Gene Expression and Cytokine Release Profiles Highlight the Heterogeneity of Distinct Subsets of Adipose Tissue-Derived Stem Cells in the Subcutaneous and Visceral Adipose Tissue in Humans. <i>PLoS ONE</i> , 2013, 8, e57892.	2.5	51
74	Dexamethasone enhances insulin-like growth factor-I effects on skeletal muscle cell proliferation. Role of specific intracellular signaling pathways.. <i>Journal of Clinical Investigation</i> , 1995, 96, 1473-1483.	8.2	51
75	Efficacy and safety of flash glucose monitoring in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001092.	2.8	50
76	Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study. <i>Atherosclerosis</i> , 2018, 277, 413-418.	0.8	48
77	Reduced SIRT1 and SIRT2 expression promotes adipogenesis of human visceral adipose stem cells and associates with accumulation of visceral fat in human obesity. <i>International Journal of Obesity</i> , 2020, 44, 307-319.	3.4	48
78	Performance of contrast-enhanced ultrasound (CEUS) in assessing thyroid nodules: a systematic review and meta-analysis using histological standard of reference. <i>Radiologia Medica</i> , 2020, 125, 406-415.	7.7	48
79	Association of <i>TCF7L2</i> gene variants with low GAD autoantibody titre in LADA subjects (NIRAD) <i>Tj ETQq1 1 0.784314 rgBT /Over</i>	2.3	47
80	The IGF-I/IGF-I Receptor Pathway: Implications in the Pathophysiology of Thyroid Cancer. <i>Current Medicinal Chemistry</i> , 2005, 12, 2881-2891.	2.4	46
81	Abnormalities of Insulin-Like Growth Factor-I Signaling and Impaired Cell Proliferation in Osteoblasts from Subjects with Osteoporosis. <i>Endocrinology</i> , 2008, 149, 1302-1313.	2.8	46
82	Abnormalities of IGF-I signaling in the pathogenesis of diseases of the bone, brain, and fetoplacental unit in humans. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2008, 295, E991-E999.	3.5	45
83	Biological specificity of visceral adipose tissue and therapeutic intervention. <i>Archives of Physiology and Biochemistry</i> , 2008, 114, 277-286.	2.1	45
84	Heterogeneity and Similarities in GLP-1 Receptor Agonist Cardiovascular Outcomes Trials. <i>Trends in Endocrinology and Metabolism</i> , 2019, 30, 578-589.	7.1	43
85	Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis. <i>Scientific Reports</i> , 2019, 9, 19351.	3.3	43
86	Changes in tyrosine phosphorylation of insulin receptors and a 170,000 molecular weight nonreceptor protein in vivo in skeletal muscle of streptozotocin-induced diabetic rats: effects of insulin and glucose. <i>Endocrinology</i> , 1992, 130, 1433-1444.	2.8	43
87	Effect of an L-Carnitine-Containing Peritoneal Dialysate on Insulin Sensitivity in Patients Treated With CAPD: A 4-Month, Prospective, Multicenter Randomized Trial. <i>American Journal of Kidney Diseases</i> , 2013, 62, 929-938.	1.9	42
88	Glucose Control and Vascular Outcomes in Type 2 Diabetes: Is the Picture Clear?. <i>Diabetes Care</i> , 2016, 39, S187-S195.	8.6	42
89	Role of the p66Shc Isoform in Insulin-like Growth Factor I Receptor Signaling through MEK/Erk and Regulation of Actin Cytoskeleton in Rat Myoblasts. <i>Journal of Biological Chemistry</i> , 2004, 279, 43900-43909.	3.4	41
90	Analysis of Insulin Sensitivity in Adipose Tissue of Patients with Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 4037-4042.	3.6	40

#	ARTICLE	IF	CITATIONS
91	The p66Shc redox adaptor protein is induced by saturated fatty acids and mediates lipotoxicity-induced apoptosis in pancreatic beta cells. <i>Diabetologia</i> , 2015, 58, 1260-1271.	6.3	40
92	Dietary intake and major food sources of polyphenols in people with type 2 diabetes: The TOSCA.IT Study. <i>European Journal of Nutrition</i> , 2018, 57, 679-688.	3.9	38
93	Therapeutic Efficacy of Lixisenatide Added to Basal Insulin is Greater When FPG is Well Controlled. <i>Canadian Journal of Diabetes</i> , 2013, 37, S31.	0.8	37
94	Pathogenetic Mechanisms and Cardiovascular Risk. <i>Diabetes Care</i> , 2012, 35, 2607-2612.	8.6	36
95	Italian consensus for the classification and reporting of thyroid cytology: the risk of malignancy between indeterminate lesions at low or high risk. A systematic review and meta-analysis. <i>Endocrine</i> , 2019, 63, 430-438.	2.3	36
96	Timing of Fetal Growth Acceleration in Women with Insulin-Dependent Diabetes. <i>Fetal Diagnosis and Therapy</i> , 2003, 18, 437-441.	1.4	34
97	Relation between sex hormones and serum lipoprotein and lipoprotein(a) concentrations in premenopausal obese women.. <i>Arteriosclerosis and Thrombosis: A Journal of Vascular Biology</i> , 1993, 13, 675-679.	3.9	33
98	Insulin signalling in human adipose tissue. <i>Archives of Physiology and Biochemistry</i> , 2006, 112, 82-88.	2.1	33
99	p66Shc, a multifaceted protein linking Erk signalling, glucose metabolism, and oxidative stress. <i>Archives of Physiology and Biochemistry</i> , 2011, 117, 116-124.	2.1	33
100	PKB/Akt and MAPK/ERK phosphorylation is highly induced by inositols: Novel potential insights in endothelial dysfunction in preeclampsia. <i>Pregnancy Hypertension</i> , 2017, 10, 107-112.	1.4	32
101	Dysmetabolic adipose tissue in obesity: morphological and functional characteristics of adipose stem cells and mature adipocytes in healthy and unhealthy obese subjects. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 921-941.	3.3	32
102	Glucagon-Like Peptide-1 Counteracts Oxidative Stress-Dependent Apoptosis of Human Cardiac Progenitor Cells by Inhibiting the Activation of the c-Jun N-terminal Protein Kinase Signaling Pathway. <i>Endocrinology</i> , 2012, 153, 5770-5781.	2.8	31
103	Management of patients with diabetes and obesity in the COVID-19 era: Experiences and learnings from South and East Europe, the Middle East, and Africa. <i>Diabetes Research and Clinical Practice</i> , 2021, 172, 108617.	2.8	31
104	Cardiovascular and Renal Effectiveness of GLP-1 Receptor Agonists vs. Other Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Real-World Studies. <i>Metabolites</i> , 2022, 12, 183.	2.9	31
105	Human adipose tissue stem cells: relevance in the pathophysiology of obesity and metabolic diseases and therapeutic applications. <i>Expert Reviews in Molecular Medicine</i> , 2012, 14, e19.	3.9	30
106	Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing's syndrome and acromegaly. <i>Journal of Endocrinological Investigation</i> , 2016, 39, 235-255.	3.3	30
107	Independent Influence of Insulin, Catecholamines, and Thyroid Hormones on Metabolic Syndrome. <i>Obesity</i> , 2008, 16, 2405-2411.	3.0	29
108	TNF α Signals via p66Shc to Induce E-Selectin, Promote Leukocyte Transmigration and Enhance Permeability in Human Endothelial Cells. <i>PLoS ONE</i> , 2013, 8, e81930.	2.5	29

#	ARTICLE	IF	CITATIONS
109	<i>In Vivo</i> Insulin Signaling in the Myocardium of Streptozotocin-Diabetic Rats: Opposite Effects of Diabetes on Insulin Stimulation of Glycogen Synthase and c-Fos ¹ . <i>Endocrinology</i> , 1999, 140, 1141-1150.	2.8	28
110	Pathophysiology of type 2 diabetes: Rationale for different oral antidiabetic treatment strategies. <i>Diabetes Research and Clinical Practice</i> , 2005, 68, S22-S29.	2.8	28
111	Involvement of the p66 ^{Shc} protein in glucose transport regulation in skeletal muscle myoblasts. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2009, 296, E228-E237.	3.5	28
112	Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide. <i>Frontiers in Endocrinology</i> , 2021, 12, 645507.	3.5	28
113	Insulin-stimulated cell growth in insulin receptor substrate-1 [−] deficient ZR-75-1 cells is mediated by a phosphatidylinositol-3-kinase [−] independent pathway. , 1998, 70, 268-280.		26
114	A family history of Type 2 diabetes is associated with increased plasma levels of C-reactive protein in non-smoking healthy adult women. <i>Diabetic Medicine</i> , 2002, 19, 689-692.	2.3	26
115	Gut: A key player in the pathogenesis of type 2 diabetes?. <i>Critical Reviews in Food Science and Nutrition</i> , 2018, 58, 1294-1309.	10.3	26
116	Glucose-lowering therapy and cardiovascular outcomes in patients with type 2 diabetes mellitus and acute coronary syndrome. <i>Diabetes and Vascular Disease Research</i> , 2019, 16, 399-414.	2.0	26
117	Adipose Tissue Inflammation and Pulmonary Dysfunction in Obesity. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7349.	4.1	26
118	GLP-1: benefits beyond pancreas. <i>Journal of Endocrinological Investigation</i> , 2014, 37, 1143-1153.	3.3	25
119	GLP-1 Receptor Activation Inhibits Palmitate-Induced Apoptosis via Ceramide in Human Cardiac Progenitor Cells. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 4136-4147.	3.6	25
120	Functional loss of pancreatic islets in type 2 diabetes: How can we halt it?. <i>Metabolism: Clinical and Experimental</i> , 2020, 110, 154304.	3.4	25
121	Distribution of cardiovascular disease and retinopathy in patients with type 2 diabetes according to different classification systems for chronic kidney disease: a cross-sectional analysis of the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study. <i>Cardiovascular Diabetology</i> . 2014. 13. 59.	6.8	24
122	Efficacy of Vandetanib in Treating Locally Advanced or Metastatic Medullary Thyroid Carcinoma According to RECIST Criteria: A Systematic Review and Meta-Analysis. <i>Frontiers in Endocrinology</i> , 2018, 9, 224.	3.5	24
123	The importance of the initial period of basal insulin titration in people with diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 722-733.	4.4	24
124	Islet transplantation restores normal levels of insulin receptor and substrate tyrosine phosphorylation and phosphatidylinositol 3-kinase activity in skeletal muscle and myocardium of streptozocin-induced diabetic rats. <i>Diabetes</i> , 1999, 48, 801-812.	0.6	23
125	Links between Metabolic Syndrome and Cardiovascular Autonomic Dysfunction. <i>Experimental Diabetes Research</i> , 2012, 2012, 1-9.	3.8	23
126	HypoparaNet: A Database of Chronic Hypoparathyroidism Based on Expert Medical-Surgical Centers in Italy. <i>Calcified Tissue International</i> , 2018, 103, 151-163.	3.1	23

#	ARTICLE	IF	CITATIONS
127	Propensity score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100%U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2821-2829.	4.4	23
128	Differential indication for SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with established atherosclerotic heart disease or at risk for congestive heart failure. <i>Metabolism: Clinical and Experimental</i> , 2020, 104, 154045.	3.4	23
129	The ultrasound assessment of adipose tissue deposition in fetuses of well controlled insulin-dependent diabetic pregnancies. <i>Diabetic Medicine</i> , 2003, 20, 858-862.	2.3	22
130	Prospective, randomized trial on intensive SMBG management added value in non-insulin-treated T2DM patients (PRISMA): a study to determine the effect of a structured SMBG intervention. <i>Acta Diabetologica</i> , 2013, 50, 663-672.	2.5	22
131	Long-Term Exposure of Pancreatic β -Cells to Palmitate Results in SREBP-1C-Dependent Decreases in GLP-1 Receptor Signaling via CREB and AKT and Insulin Secretory Response. <i>Endocrinology</i> , 2016, 157, 2243-2258.	2.8	22
132	NANOG Plays a Hierarchical Role in the Transcription Network Regulating the Pluripotency and Plasticity of Adipose Tissue-Derived Stem Cells. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1107.	4.1	22
133	Primary hyperparathyroidism with surgical indication and negative or equivocal scintigraphy: safety and reliability of PTH washout. A systematic review and meta-analysis. <i>European Journal of Endocrinology</i> , 2019, 181, 245-253.	3.7	22
134	cDNA Cloning of the Rat IGF I Receptor: Structural Analysis of Rat and Human IGF I and Insulin Receptors Reveals Differences in Alternative Splicing and Receptor-Specific Domain Conservation. <i>Biochemical and Biophysical Research Communications</i> , 1994, 202, 1038-1046.	2.1	21
135	GLP-1: a new approach for type 2 diabetes therapy. <i>Diabetes Research and Clinical Practice</i> , 2006, 74, S152-S155.	2.8	21
136	Irisin increases the expression of anorexigenic and neurotrophic genes in mouse brain. <i>Diabetes/Metabolism Research and Reviews</i> , 2020, 36, e3238.	4.0	21
137	Impaired Leptin Signalling in Obesity: Is Leptin a New Thermolipokine?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6445.	4.1	21
138	Feasibility and Effectiveness in Clinical Practice of a Multifactorial Intervention for the Reduction of Cardiovascular Risk in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2013, 36, 2566-2572.	8.6	20
139	Effects of CPAP on Testosterone Levels in Patients With Obstructive Sleep Apnea: A Meta-Analysis Study. <i>Frontiers in Endocrinology</i> , 2019, 10, 551.	3.5	20
140	Irisin and Incretin Hormones: Similarities, Differences, and Implications in Type 2 Diabetes and Obesity. <i>Biomolecules</i> , 2021, 11, 286.	4.0	20
141	Lower risk of death and cardiovascular events in patients with diabetes initiating glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors: A real-world study in two Italian cohorts. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1484-1495.	4.4	20
142	Early prediction of pancreatic cancer from new-onset diabetes: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Societ� Italiana Endocrinologia (SIE)/Societ� Italiana Farmacologia (SIF) multidisciplinary consensus position paper. <i>ESMO Open</i> , 2021, 6, 100155.	4.5	20
143	Fine-needle aspiration to diagnose primary thyroid lymphomas: a systematic review and meta-analysis. <i>European Journal of Endocrinology</i> , 2019, 180, 177-187.	3.7	20
144	SGLT-2 inhibitors as cardio-renal protective agents. <i>Metabolism: Clinical and Experimental</i> , 2022, 127, 154937.	3.4	20

#	ARTICLE	IF	CITATIONS
145	Expression and Secretion of the Atrial Natriuretic Peptide in Human Adipose Tissue and Preadipocytes*. <i>Obesity</i> , 2007, 15, 2181-2189.	3.0	19
146	Treatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short-acting and other glucagon-like peptide-1 receptor agonists. <i>Diabetes/Metabolism Research and Reviews</i> , 2016, 32, 497-511.	4.0	19
147	Lysine 63 ubiquitination is involved in the progression of tubular damage in diabetic nephropathy. <i>FASEB Journal</i> , 2017, 31, 308-319.	0.5	19
148	Reduction of hypoglycaemia, lifestyle modifications and psychological distress during lockdown following SARS-CoV-2 outbreak in type 1 diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 2021, 37, e3404.	4.0	19
149	Increased free testosterone but normal 5 α -reduced testosterone metabolites in obese premenopausal women. <i>Clinical Endocrinology</i> , 1992, 36, 553-558.	2.4	18
150	Multifactorial intervention in Type 2 diabetes: The promise of incretin-based therapies. <i>Journal of Endocrinological Investigation</i> , 2011, 34, 69-77.	3.3	18
151	Pharmacologic agents for type 2 diabetes therapy and regulation of adipogenesis. <i>Archives of Physiology and Biochemistry</i> , 2013, 119, 139-150.	2.1	18
152	The p66Shc protein controls redox signaling and oxidation-dependent DNA damage in human liver cells. <i>American Journal of Physiology - Renal Physiology</i> , 2015, 309, G826-G840.	3.4	18
153	The Burden of Structured Self-Monitoring of Blood Glucose on Diabetes-Specific Quality of Life and Locus of Control in Patients with Noninsulin-Treated Type 2 Diabetes: The PRISMA Study. <i>Diabetes Technology and Therapeutics</i> , 2016, 18, 421-428.	4.4	18
154	Deregulation of autophagy under hyperglycemic conditions is dependent on increased lysine 63 ubiquitination: a candidate mechanism in the progression of diabetic nephropathy. <i>Journal of Molecular Medicine</i> , 2018, 96, 645-659.	3.9	18
155	Effects of Extra Virgin Olive Oil Polyphenols on Beta-Cell Function and Survival. <i>Plants</i> , 2021, 10, 286.	3.5	18
156	Interventional Therapy in Diabetic Foot: Risk Factors, Clinical Events and Prognosis at One Year Follow-up (A Study of 103 Cases). <i>Pakistan Journal of Biological Sciences</i> , 2012, 15, 789-794.	0.5	18
157	Adipose Tissue Secretion Pattern Influences β -Cell Wellness in the Transition from Obesity to Type 2 Diabetes. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5522.	4.1	18
158	Evidence for two insulin-like growth factor I receptors with distinct primary structure that are differentially expressed during development. <i>Regulatory Peptides</i> , 1993, 48, 279-290.	1.9	17
159	Divergent Effects of Short-Term, Very-Low-Calorie Diet on Insulin-Like Growth Factor-I and Insulin-Like Growth Factor Binding Protein-3 Serum Concentrations in Premenopausal Women with Obesity. <i>Obesity</i> , 1998, 6, 408-415.	4.0	17
160	Wound Healing in Diabetes: Hemorheological and Microcirculatory Aspects. <i>Advances in Experimental Medicine and Biology</i> , 2011, 701, 263-269.	1.6	17
161	Cardiovascular protection with sodium-glucose cotransporter-2 inhibitors in type 2 diabetes: Does it apply to all patients?. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1481-1495.	4.4	17
162	Ladarixin, an inhibitor of the interleukin-8 receptors <sc>CXCR1</sc> and <sc>CXCR2</sc>, in new-onset type 1 diabetes: A multicentre, randomized, double-blind, placebo-controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1840-1849.	4.4	17

#	ARTICLE	IF	CITATIONS
163	Role of UBC9 in the Regulation of the Adipogenic Program in 3T3-L1 Adipocytes. <i>Endocrinology</i> , 2010, 151, 5255-5266.	2.8	16
164	Metabolic syndrome in subjects at high risk for type 2 diabetes: The genetic, physiopathology and evolution of type 2 diabetes (GENFIEV) study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2011, 21, 699-705.	2.6	16
165	Computerized Video-Capillaroscopy Alteration Related to Diabetes Mellitus and Its Complications. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1072, 363-368.	1.6	16
166	The Sentiment Analysis of Tweets as a New Tool to Measure Public Perception of Male Erectile and Ejaculatory Dysfunctions. <i>Sexual Medicine</i> , 2019, 7, 464-471.	1.6	16
167	The effects of weight loss due to gastric banding and lifestyle modification on red blood cell aggregation and deformability in severe obese subjects. <i>International Journal of Obesity</i> , 2012, 36, 342-347.	3.4	15
168	High Frequency of Incidental Diagnosis of Extrathyroidal Neoplastic Diseases at the Fine-Needle Aspiration Biopsy of Laterocervical Lymph Nodes in Patients with Thyroid Nodules. <i>Thyroid</i> , 2001, 11, 65-71.	4.5	14
169	Human adipose tissue precursor cells: a new factor linking regulation of fat mass to obesity and type 2 diabetes?. <i>Archives of Physiology and Biochemistry</i> , 2009, 115, 218-226.	2.1	14
170	The METABOLIC Study: Multidimensional assessment of health and functional status in older patients with type 2 diabetes taking oral antidiabetic treatment. <i>Diabetes and Metabolism</i> , 2013, 39, 236-243.	2.9	14
171	Clusterin transcript variants expression in thyroid tumor: a potential marker of malignancy?. <i>BMC Cancer</i> , 2015, 15, 349.	2.6	14
172	A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 763-772.	3.1	14
173	Serum Homocysteine Levels in Men with and without Erectile Dysfunction: A Systematic Review and Meta-Analysis. <i>International Journal of Endocrinology</i> , 2018, 2018, 1-7.	1.5	14
174	Efficacy and safety of insulin glargine/lixisenatide (iGlarLixi) fixed-ratio combination in older adults with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 236-242.	2.3	14
175	Titratable fixed-ratio combination of insulin glargine plus lixisenatide: A simplified approach to glycemic control in type 2 diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 2020, 170, 108478.	2.8	14
176	Antineoplastic dosing in overweight and obese cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Societ� Italiana Endocrinologia (SIE)/Societ� Italiana Farmacologia (SIF) multidisciplinary consensus position paper. <i>ESMO Open</i> , 2021, 6, 100153.	4.5	13
177	Insulin-resistant MDA-MB231 human breast cancer cells contain a tyrosine kinase inhibiting activity. <i>Molecular Endocrinology</i> , 1993, 7, 1667-1676.	3.7	13
178	In Vivo Insulin Signaling in the Myocardium of Streptozotocin-Diabetic Rats: Opposite Effects of Diabetes on Insulin Stimulation of Glycogen Synthase and c-Fos. <i>Endocrinology</i> , 1999, 140, 1141-1150.	2.8	12
179	Metabolic disorders and gastroenteropancreatic-neuroendocrine tumors (GEP-NETS): How do they influence each other? An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103572.	4.4	12
180	Adipose tissue function and dysfunction: organ cross talk and metabolic risk. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2009, 297, E975-E976.	3.5	11

#	ARTICLE	IF	CITATIONS
181	Use of isoxsuprine hydrochloride as a tocolytic agent in the treatment of preterm labour: a systematic review of previous literature. <i>Arzneimittelforschung</i> , 2010, 60, 415-420.	0.4	11
182	Association between Follicular Fluid Leptin and Serum Insulin Levels in Nonoverweight Women with Polycystic Ovary Syndrome. <i>BioMed Research International</i> , 2014, 2014, 1-7.	1.9	11
183	Rare diseases in clinical endocrinology: a taxonomic classification system. <i>Journal of Endocrinological Investigation</i> , 2015, 38, 193-259.	3.3	11
184	Long-acting insulin analog detemir displays reduced effects on adipocyte differentiation of human subcutaneous and visceral adipose stem cells. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016, 26, 333-344.	2.6	11
185	Effect of once-weekly dulaglutide versus insulin glargine in people with type 2 diabetes and different baseline glycaemic patterns: A post hoc analysis of the AWARD clinical trial. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2570-2575.	4.4	11
186	<sc>iGlarLixi</sc> effectively reduces residual hyperglycaemia in patients with type 2 diabetes on basal insulin: A post hoc analysis from the <sc>LixiLan</sc> study. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1683-1689.	4.4	11
187	The diabetic lung: An easy target for <sc>SARS-CoV</sc>? <i>Diabetes/Metabolism Research and Reviews</i> , 2020, 36, e3346.	4.0	11
188	Effect of Family History of Type 2 Diabetes on White Blood Cell Count in Adult Women. <i>Obesity</i> , 2003, 11, 1232-1237.	4.0	10
189	Reversal of foetal hydrops and foetal tachyarrhythmia associated with maternal diabetic coma. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2000, 93, 33-35.	1.1	9
190	Nateglinide provides tighter glycaemic control than glyburide in patients with Type 2 diabetes with prevalent postprandial hyperglycaemia. <i>Diabetic Medicine</i> , 2011, 28, 560-566.	2.3	9
191	Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing's syndrome and acromegaly. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016, 26, 85-102.	2.6	9
192	Report from the CVOT Summit 2020: new cardiovascular and renal outcomes. <i>Cardiovascular Diabetology</i> , 2021, 20, 75.	6.8	9
193	Role of Glucose-Lowering Medications in Erectile Dysfunction. <i>Journal of Clinical Medicine</i> , 2021, 10, 2501.	2.4	9
194	Structured self-monitoring of blood glucose is associated with more appropriate therapeutic interventions than unstructured self-monitoring: A novel analysis of data from the PRISMA trial. <i>Diabetes Research and Clinical Practice</i> , 2021, 181, 109070.	2.8	9
195	Managing weight and glycaemic targets in people with type 2 diabetes—How far have we come?. <i>Endocrinology, Diabetes and Metabolism</i> , 2022, 5, e00330.	2.4	9
196	A six month mitotane course induced sustained correction of hypercortisolism in a young woman with PPNAD and Carney complex. <i>Journal of Endocrinological Investigation</i> , 2005, 28, 54-60.	3.3	8
197	Exploiting the pleiotropic actions of GLP-1 for the management of type 2 diabetes mellitus and its complications. <i>Diabetes Research and Clinical Practice</i> , 2007, 78, S59-S67.	2.8	8
198	Factors associated with improved glycemic control following continuous subcutaneous insulin infusion therapy in patients with type 2 diabetes uncontrolled with bolus-basal insulin regimens: <sc>A</sc>n analysis from the <sc>OpT2mise</sc> randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1490-1494.	4.4	8

#	ARTICLE	IF	CITATIONS
199	Metabolic control and complications in Italian people with diabetes treated with continuous subcutaneous insulin infusion. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2018, 28, 335-342.	2.6	8
200	Achievement of glycaemic control is associated with improvements in lipid profile with iGlarLixi versus iGlar: A post hoc analysis of the LixiLan trial. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2712-2717.	4.4	8
201	Commentary: Glucose control: Not just a bystander in GLP-1RA-mediated cardiovascular protection. <i>Metabolism: Clinical and Experimental</i> , 2020, 109, 154272.	3.4	8
202	Mini Review: Effect of GLP-1 Receptor Agonists and SGLT-2 Inhibitors on the Growth Hormone/IGF Axis. <i>Frontiers in Endocrinology</i> , 2022, 13, 846903.	3.5	8
203	Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes. <i>Cardiovascular Diabetology</i> , 2022, 21, 50.	6.8	8
204	Lipodystrophic Diabetes Mellitus: a Lesson for Other Forms of Diabetes?. <i>Current Diabetes Reports</i> , 2015, 15, 12.	4.2	7
205	A telemedicine-based approach with real-time transmission of blood glucose data improves metabolic control in insulin-treated diabetes: the DIAMONDS randomized clinical trial. <i>Journal of Endocrinological Investigation</i> , 2022, 45, 1663-1671.	3.3	7
206	Similar glycaemic control and less hypoglycaemia during active titration after insulin initiation with glargine 300 units/mL and degludec 100 units/mL: A subanalysis of the BRIGHT study. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 346-354.	4.4	6
207	Diabetes in the Time of COVID-19: A Twitter-Based Sentiment Analysis. <i>Journal of Diabetes Science and Technology</i> , 2020, 14, 1131-1132.	2.2	6
208	Late Endocrine and Metabolic Sequelae and Long-Term Monitoring of Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors: A Systematic Review by the Fondazione Italiana Linfomi. <i>Cancers</i> , 2022, 14, 1439.	3.7	6
209	The p66Shc Protein Mediates Insulin Resistance and Secretory Dysfunction in Pancreatic β -Cells Under Lipotoxic Conditions. <i>Diabetes</i> , 2022, 71, 1763-1771.	0.6	6
210	Insulin signaling in adipose tissue of patients with primary aldosteronism. <i>Journal of Endocrinological Investigation</i> , 2011, 34, 86-89.	3.3	5
211	Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus: A Post Hoc Analysis. <i>Diabetes Therapy</i> , 2016, 7, 583-590.	2.5	5
212	The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHEES): Baseline Patient-Reported Outcomes. <i>Diabetes Therapy</i> , 2020, 11, 2383-2399.	2.5	5
213	Postprandial glucose and HbA1c are associated with severity of obstructive sleep apnoea in non-diabetic obese subjects. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 2741-2748.	3.3	5
214	The European Association for the Study of Obesity (EASO) Endorses the Milan Charter on Urban Obesity. <i>Obesity Facts</i> , 2021, 14, 163-168.	3.4	5
215	Salt reduction and iodine intake in Italy. <i>Journal of Endocrinological Investigation</i> , 2022, 45, 883-885.	3.3	5
216	GLP-1 Receptor Agonists for Cardiovascular Protection: A Matter of Time. <i>Diabetes Care</i> , 2022, 45, e30-e31.	8.6	5

#	ARTICLE	IF	CITATIONS
217	Concomitant iGlarLixi and Sodium-Glucose Co-transporter-2 Inhibitor Therapy in Adults with Type 2 Diabetes: LixiLan-G Trial and Real-World Evidence Results. <i>Diabetes Therapy</i> , 2022, 13, 205-215.	2.5	5
218	Relationship between insulin receptor tyrosine kinase activity and internalization in monocytes of non-insulin-dependent diabetes mellitus patients. <i>Metabolism: Clinical and Experimental</i> , 1993, 42, 882-887.	3.4	4
219	Inhibition of Lysine 63 Ubiquitination Prevents the Progression of Renal Fibrosis in Diabetic DBA/2J Mice. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5194.	4.1	4
220	HGF and M-CSF modulate adhesion of MDA-231 breast cancer cell by increasing osteopontin secretion. <i>Journal of Biological Regulators and Homeostatic Agents</i> , 2002, 16, 190-5.	0.7	4
221	Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed-ratio combination: a post hoc analysis of the LixiLan [®] and LixiLan [®] L trials. <i>Diabetic Medicine</i> , 2020, 37, 256-266.	2.3	3
222	Clinical aggressiveness of incidental and non-incidental thyroid cancer. <i>Journal of Endocrinological Investigation</i> , 2011, 34, 599-603.	3.3	3
223	Response to Comment on: Bosi et al. Intensive Structured Self-Monitoring of Blood Glucose and Glycemic Control in Noninsulin-Treated Type 2 Diabetes: The PRISMA Randomized Trial. <i>Diabetes Care</i> 2013;36:2887-2894. <i>Diabetes Care</i> , 2013, 36, e218-e218.	8.6	2
224	RAS/BRAF mutational status in familial non-medullary thyroid carcinomas: A retrospective study. <i>Oncology Letters</i> , 2015, 10, 1875-1881.	1.8	2
225	<sc>S</sc>odium-glucose co-transporter-2 inhibitors and protection from cardiovascular death: Is it all about heart failure?. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2194-2196.	4.4	2
226	Different gene expression in human heart tissue and progenitor cells from control and diabetic subjects: relevance to the pathogenesis of human diabetic cardiomyopathy. <i>Surgical Technology International</i> , 2010, 19, 165-74.	0.2	2
227	Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. <i>European Journal of Endocrinology</i> , 2010, 163, 963.	3.7	1
228	Insulin Glargine U100 Utilization in Patients with Type 2 Diabetes in an Italian Real-World Setting: A Retrospective Study. <i>Journal of Diabetes Research</i> , 2019, 2019, 1-10.	2.3	1
229	Patient-reported outcomes in elderly patients with type 2 diabetes mellitus treated with dual oral therapy: a multicenter, observational study from Italy. <i>Current Medical Research and Opinion</i> , 2020, 36, 555-562.	1.9	1
230	Exercise and apulian hypocaloric diet affect adipokine changes and gastric banding-induced weight loss: A prospective study on severe obese subjects. <i>Annals of Medicine and Surgery</i> , 2020, 52, 10-15.	1.1	1
231	Editorial: Reviews and Novel Clinical Perspectives on Semaglutide: A GLP-1 Receptor Agonist With Both Injectable and Oral Formulations. <i>Frontiers in Endocrinology</i> , 2021, 12, 760153.	3.5	1
232	Updating obesity management strategies: an audit of Italian specialists. <i>Eating and Weight Disorders</i> , 2022, 27, 2653-2663.	2.5	1
233	Regulation of Insulin Signaling in the Skeletal and Cardiac Muscles of Diabetic Rats. , 1998, 14, 157-160.		0
234	Editorial [Hot Topic: Targeting the IGF-I Receptor Signaling Pathway: Implications for Human Cancer Therapy (Executive Editors: A. Ciampolillo and F. Giorgino)]. <i>Current Pharmaceutical Design</i> , 2007, 13, 661-662.	1.9	0

#	ARTICLE	IF	CITATIONS
235	Corrigendum to "Adipose tissue, metabolic syndrome and polycystic ovary syndrome: from pathophysiology to treatment" [Reprod. Biomed. Online 19 (2009) 552-563]. Reproductive BioMedicine Online, 2012, 25, 335.	2.4	0
236	A master course on "Methodologies for Bio-Medical research in diabetes". Archives of Physiology and Biochemistry, 2013, 119, 137-138.	2.1	0
237	Reductions in Post-Prandial Glucagon by the GLP-1 Receptor Agonist Lixisenatide Correlate to Reductions in PPG and A1C in Patients with Type 2 Diabetes Mellitus. Canadian Journal of Diabetes, 2014, 38, S11-S12.	0.8	0
238	Intensive glucose-lowering results in increased cardiovascular mortality in younger but not older individuals with type 2 diabetes. Evidence-Based Medicine, 2014, 19, 210-210.	0.6	0
239	Glycated haemoglobin does not accurately predict average capillary glucose in non insulin-treated type 2 diabetes: The PRISMA study experience. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 169-170.	2.6	0
240	Cover Image, Volume 21, Issue 12. Diabetes, Obesity and Metabolism, 2019, 21, i.	4.4	0
241	Thermal ablation meta-analysis: the need of careful appraisal of meta-analysis methodology. Endocrine, 2020, 67, 270-271.	2.3	0
242	Treatment effects of once-weekly dulaglutide versus insulin glargine in patients with different baseline glycemic patterns (based on high/low fasting or high/low postprandial glucose): A post hoc analysis of the AWARD-2 clinical trial. , 2019, 14, .		0
243	Lipids and Glucose Metabolism. Trends in Andrology and Sexual Medicine, 2020, , 155-162.	0.1	0
244	The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide & Liraglutide in Type 2 Diabetes Patients (TROPHIES): 12-month data analysis. Diabetologie Und Stoffwechsel, 2022, , .	0.0	0
245	Therapieintensivierung bei Typ-2-Diabetespatienten mit basalunterstützter oraler Therapie (BOT): Hypoglykämien als Funktion des HbA1c in der SoliMix-Studie. Diabetologie Und Stoffwechsel, 2022, , .	0.0	0